Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3941321 | 1.00 | LMNA (0.47) | LMNAHAO1RAB9ANPC1L3MBTL1 | |
| SCHEMBL6201900 | 0.86 | RAB9A (0.59) | LMNARAB9ANPC1L3MBTL1PTPN1 | |
| SCHEMBL6386624 | 0.85 | SRD5A2 (0.57) | HAO1RAB9ANPC1L3MBTL1HTT | |
| SCHEMBL7832348 | 0.85 | NPC1 (0.65) | LMNAHAO1RAB9ANPC1L3MBTL1 | |
| SCHEMBL7832647 | 0.83 | HSP90AA1 (0.49) | LMNAHAO1RAB9ANPC1L3MBTL1 | |
| SCHEMBL6513182 | 0.83 | HSP90AA1 (0.49) | LMNAHAO1RAB9ANPC1L3MBTL1 | |
| SCHEMBL7850760 | 0.83 | RAB9A (0.68) | LMNAHAO1RAB9ANPC1L3MBTL1 | |
| SCHEMBL3940582 | 0.83 | RAB9A (0.68) | LMNAHAO1RAB9ANPC1L3MBTL1 | |
| SCHEMBL6168844 | 0.83 | MAPT (0.51) | LMNAHAO1RAB9ANPC1L3MBTL1 | |
| SCHEMBL3939694 | 0.83 | MAPT (0.61) | LMNAHAO1RAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1466897-B1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | DIPHARMA FRANCIS SRL (IT) | 2008-12-17 | — | — | EP | claimed |
| US-6998490-B2 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. (IT) | 2006-02-14 | — | — | US | claimed |
| EP-1466897-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | Dipharma S.p.A. (IT) | 2004-10-13 | — | — | EP | claimed |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. | 2004-09-30 | — | — | US | claimed |
| EP-1466897-B1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | DIPHARMA FRANCIS SRL (IT) | 2008-12-17 | — | — | EP | disclosed |
| EP-1005460-B1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LAB (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6998490-B2 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. (IT) | 2006-02-14 | — | — | US | disclosed |
| US-20050272036-A1 | Ketones | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| US-6919353-B2 | Substituted 8-arylquinolune PDE4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2005-07-19 | — | — | US | disclosed |
| EP-1549600-A1 | KETONES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| EP-1404330-B1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-06-01 | — | — | EP | disclosed |
| EP-1466897-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | Dipharma S.p.A. (IT) | 2004-10-13 | — | — | EP | disclosed |
| WO-1996003392-A1 | SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| US-5474995-A | Nonsteroidal, antiinflammatory agents | MERCK FROSST CANADA, INC. (CA) | 1995-12-12 | — | — | US | disclosed |
| WO-1995018799-A1 | PHENYL HETEROCYCLES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1995-07-13 | — | — | WO | disclosed |
| US-5380738-A | Side effect reduction | MONSANTO COMPANY (US) | 1995-01-10 | — | — | US | disclosed |
| WO-1995000501-A2 | PHENYL HETEROCYCLES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1995-01-05 | — | — | WO | disclosed |
| WO-1994027980-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1994-12-08 | — | — | WO | disclosed |
| US-5082974-A | 3-HALOGENO-2,3-DIPHENYLACRYLALDEHYDE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND A PHARMACEUTICAL COMPOSITION FOR TREATING HYPERLIPIDEMI | OTSUKA PHARACEUTICAL FACTORY, INC. (JP) | 1992-01-21 | — | — | US | disclosed |
| EP-0424541-A1 | 3-HALOGENO-2,3-DIPHENYLACRYLALDEHYDE DERIVATIVE, METHOD OF PRODUCTION THEREOF AND CURING AGENT FOR HYPERLIPIDEMIA | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1991-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | STS, MPST, SULT2A1 | LMNA 4700/4885HAO1 140/4885RAB9A 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.